Results 91 to 100 of about 3,924 (164)

Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1101-1110, October 2026.
NAT2 encodes arylamine N‐acetyltransferase 2, a key enzyme in the phase II metabolism of arylamines and arylhydrazines. NAT2 is highly polymorphic, resulting in variable distributions of rapid and poor metabolizers across global populations. Here, we detail the process undertaken by the Clinical Pharmacogenetics Implementation Consortium (CPIC) NAT2 ...
Bailey M. Tibben   +10 more
wiley   +1 more source

Dapsone induced methemoglobinemia [PDF]

open access: yes
Increase in levels of methemoglobin is termed as methemoglobinemia which leads to organ level hypoxia. It can be congenital or acquired. In this case report we present a case of a middle-aged female with methemoglobinemia due to dapsone overdose and how ...
Narula, Shubhank   +2 more
core   +1 more source

Selective IL‐23 Inhibition in Conventional Treatment‐Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study

open access: yesInternational Journal of Dermatology, Volume 65, Issue 10, Page 2055-2065, October 2026.
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini   +25 more
wiley   +1 more source

Tocilizumab for severe and refractory mucous membrane pemphigoid

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1682-1691, October 2026.
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt   +20 more
wiley   +1 more source

Why now? Delayed drug-induced pancreatitis due to dapsone for dermatitis herpetiformis

open access: yesJournal of Community Hospital Internal Medicine Perspectives, 2018
Drug-induced pancreatitis can be caused by a wide array of medications. In fact, the diagnosis is likely commonly missed due to the difficulty in diagnosing one agent as the sole cause.
Youssef Yousry Soliman   +2 more
doaj   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn   +17 more
wiley   +1 more source

Nanoemulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation

open access: yesInternational Journal of Nanomedicine, 2013
Vinícius Raphael de Almeida Borges, Alice Simon, Adrian Ricardo Cuello Sena, Lúcio Mendes Cabral, Valéria Pereira de Sousa Department of Pharmaceutics, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de ...
Borges VRA   +4 more
doaj  

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima   +48 more
wiley   +1 more source

Designing dapsone polymer conjugates for controlled drug delivery [PDF]

open access: yes, 2015
Polymer-drug conjugates have significantly influenced polymer therapeutics over the last decade via controlled pharmacokinetics. Dapsone (4,4'-diamino diphenylsulphone) is not only widely used in the treatment of leprosy but forms an essential component ...
Fernandez-Gutierrez, Mar   +9 more
core   +1 more source

The State of Shared Decision‐Making in Immune Thrombocytopenia: A Narrative Review and Health Care Provider Perspective

open access: yesHealth Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Advances in the treatment of immune thrombocytopenia (ITP) have broadened the landscape of treatment options for patients. Shared decision‐making, a collaborative process between a patient and their health care team, is encouraged for these patients. The ultimate goal of shared decision‐making is to personalize treatment to
Shivi Jain   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy